31 Breast Cancer Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Breast Cancer Studies in Birmingham

NCT02620852Recruiting

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended t...

Birmingham, ALNA100,000 participantsUniversity of California, San Francisco

View Study Details

NCT03053193Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing ...

Birmingham, AL30,000 participantsAgendia

View Study Details

NCT01042379Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learn...

Birmingham, ALPHASE25,000 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT05774951Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk f...

Birmingham, ALPHASE34,300 participantsAstraZeneca

View Study Details

NCT05879926Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast ...

Birmingham, ALPHASE33,960 participantsNRG Oncology

View Study Details

NCT06058377Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-I...

Birmingham, ALPHASE33,680 participantsNational Cancer Institute (NCI)

View Study Details

NCT05929768Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast canc...

Birmingham, ALPHASE32,400 participantsSWOG Cancer Research Network

View Study Details

NCT05625659Recruiting

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers...

Birmingham, ALNA2,032 participantsAmerican College of Radiology

View Study Details

NCT04852887Recruiting

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared ...

Birmingham, ALPHASE31,670 participantsNRG Oncology

View Study Details

NCT05633654Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatmen...

Birmingham, ALPHASE31,514 participantsGilead Sciences

View Study Details

NCT05827081Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on in...

Birmingham, ALPHASE31,400 participantsNovartis Pharmaceuticals

View Study Details

NCT05812807Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after p...

Birmingham, ALPHASE31,295 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT07492641Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in...

Birmingham, ALPHASE31,056 participantsBeOne Medicines

View Study Details

NCT07211178Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the canc...

Birmingham, AL900 participantsTempus AI

View Study Details

NCT07214532Recruiting

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome")...

Birmingham, ALNA725 participantsNatera, Inc.

View Study Details

NCT07287098Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. S...

Birmingham, ALPHASE2600 participantsEli Lilly and Company

View Study Details

NCT06533826Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan fol...

Birmingham, ALPHASE2357 participantsAna C Garrido-Castro, MD

View Study Details

NCT06099769Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor...

Birmingham, ALPHASE2201 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05467891Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast can...

Birmingham, ALPHASE2200 participantsOana Danciu

View Study Details

NCT06294574Recruiting

Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction

The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK....

Birmingham, ALNA150 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06369285Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-n...

Birmingham, ALPHASE2150 participantsPuma Biotechnology, Inc.

View Study Details

NCT05868226Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patie...

Birmingham, ALPHASE1124 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06855654Recruiting

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast c...

Birmingham, ALNA120 participantsUNC Lineberger Comprehensive Cancer Center

View Study Details

NCT07222267Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination ...

Birmingham, ALPHASE186 participantsBeOne Medicines

View Study Details

NCT06126276Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbocicli...

Birmingham, ALPHASE270 participantsNational Cancer Institute (NCI)

View Study Details

NCT05693766Recruiting

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone recept...

Birmingham, ALPHASE264 participantsSonya Reid

View Study Details

NCT06105684Recruiting

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a g...

Birmingham, ALPHASE240 participantsUniversity of Alabama at Birmingham

View Study Details

NCT03643861Recruiting

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy....

Birmingham, ALNA40 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04332588Recruiting

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patie...

Birmingham, ALPHASE125 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04861077Recruiting

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and pre...

Birmingham, ALEARLY_PHASE120 participantsUniversity of Alabama at Birmingham

View Study Details

NCT03321045Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to pe...

Birmingham, ALEARLY_PHASE110 participantsUniversity of Alabama at Birmingham

View Study Details

About Breast Cancer Clinical Trials in Birmingham

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 31 breast cancer clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 162,189 participants. Research is being sponsored by University of California, San Francisco, Agendia, QuantumLeap Healthcare Collaborative and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Birmingham — FAQ

Are there breast cancer clinical trials in Birmingham?

Yes, there are 31 breast cancer clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 31 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 17, 2026 from ClinicalTrials.gov